Belite Bio, Inc. ( NASDAQ: BLTE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer Nathan Mata - Chief ...

Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX ...

Outer retinal tubulation may slow lesion growth in eyes with geographic atrophy secondary to age-related macular degeneration.

A study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet ...

The investigators explained that AMN, a rare disease, is characterized by dark reddish, wedge-shaped macular lesions. 2 ...

We simultaneously track immune cell dynamics using label-free phase-contrast AOSLO at micron-level resolution. Retinal lesions were induced with 488 nm light focused onto photoreceptor (PR) outer ...

This article focuses on the pathogenesis of retinal detachment as well as the specific lesions and risk factors that lead to retinal detachment. Treatment options for both symptomatic and ...

A randomized, placebo-controlled, double-masked clinical trial of gildeuretinol in late-stage Stargardt patients showed clinically and statistically significant slowing of the growth of retinal ...

The therapies we have today for geographic atrophy protect from retinal pigment epithelium loss and lesion growth, but do not protect against vision loss.” The phase 3 ARCHER trial is currently ...